Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep. It will get there. Check out all the new clients & contracts announced in just the last 3 months.
Q3 will be a blowout:
http://microcapresearch.com/magnegas-corp-mnga-adds-u-s-army-base-growing-list/
Well...
It takes more time/comparable quarters to have "a more sophisticated look on it".
Until then- it's pretty much guesswork.
rechnerhand
GGG's filament sales began in mid March. By the end of June they doubled capacity.
Numbers in the filing don't include the more recent months with higher sales since capacity expansion, or the > 1 million in sales from Graphene Labs.
Expenses include many non-recurring costs of going public.
yes- originally got in NVIV back in December and published the first interview with "Patient #1", Jordan Fallis.
http://microcapresearch.com/invivo-therapeutics-jordan-lee-fallis/
Had a great return on those shares and am now re-entering.
Biotech may still be under pressure for a bit longer, but I love this company's technology and potential to make a huge difference in the lives of those with SCI.
Incidentally, we had several huge winners this hear besides NVIV- and subscription is free:
http://microcapresearch.com/subscribe-to-microcapresearch/
I have not been paid for the article I linked, and I am long each of the stocks in the article.
Yes, I've been paid in the past for articles, not this one.
I first wrote about NVIV when it was $2.12/share before uplifting.
Was also first person to publish interview with Pt. #1, Jordan
G Anderson
$VUZI is One of 4 Great Stocks to Buy After Friday's Big Reversal
Article:
4 Great Stocks to BUY After Biggest Intraday Upside Reversal in 4 Years: (SLTD), (VUZI), (HOTR) and (NVIV)/
SHOTR is Trading BELOW Book Value here.
That won't last!
Also- HOTR gets a nice cash dividend from the 3% ownership stake in Hooters of America- this is public information but not sure how many people know about it?
It has been paid out in September and October historically- and was just over 1/2 million last year. Just a heads up....
$SLTD is One of 4 Great Stocks to Buy After Friday's Big Reversal
Article:
4 Great Stocks to BUY After Biggest Intraday Upside Reversal in 4 Years: (SLTD), (VUZI), (HOTR) and (NVIV)/
$NVIV is One of 4 Great Stocks to Buy After Friday's Big Reversal
Article:
4 Great Stocks to BUY After Biggest Intraday Upside Reversal in 4 Years: (SLTD), (VUZI), (HOTR) and (NVIV)/
Hello rechnerhand,
Companies don't publish financial reports on the home pages of their web sites.
You won't find financial reports on the home pages of 3D Systems, Stratasys, Apple Computer, IBM, or any company because it's not done. So in reality, it would be odd if Graphene 3D Labs actually did publish financials on the home page.
As for the "going concern" statement- that's standard fare for many (even most) microcap companies. This company isn't going under. They just gained > 1 million in revenue with the a cquisition of Graphene Labs.
Hope that helps
Cigarette company (XXII) to make FDA application for modified risk tobacco product.
The interesting thing is their ciggs were actually purchased by the FDA for this study that was just released in the New England Journal of Medicine
- see news:
"The New England Journal of Medicine Publishes Landmark Study Using 22nd Century’s Proprietary Very Low Nicotine Cigarette"
http://finance.yahoo.com/news/england-journal-medicine-publishes-landmark-125600005.html
With XXII making submission to FDA using these same ciggs, they could be the ONLY company in the world with FDA's approval to market/advertise as "reduced harm" tobacco or "reduced risk tobacco" product that has been proven to help people quit smoking.
see: "22nd Century Announces Strategic Hire to Facilitate FDA Applications for Modified Risk Tobacco Product Candidates"
http://finance.yahoo.com/news/22nd-century-announces-strategic-hire-125900089.html
Interesting company to watch I think- Big Tobacco would love to make the advertising claims that XXII's patented cigarettes have shown in the study reported by NEJM- but the FDA won't allow them to
Personal note- I'm a former smoker x 20 years- I quit about 10 years ago...but still developed some mild emphysema/COPD from it- and I'm only 52.
If you smoke- please do everything you can until you quit-and stay quit. Even if it takes a dozen or more attempts- keep on trying until you are successful.
I got a few .10s other day and had bids on the 09 and .091 but no luck there.
Agreed Atlanta1
XXII will be seen as a serious buyout candidate by big tobacco soon.
Probably once FDA submission is made this fall.
See
"22nd Century Group (XXII) Cigarettes Used in Study Funded by FDA and Published by New England Journal of Medicine"
Rough market I guess?
But they closed on the acquisition, and are turning EBITDA + in Q4.
see also: Chanticleer Holdings (HOTR) Closes Little Big Burger Acquisition, Turning EBITDA +
wow- dshade too- the whole clan is here.
Good sign!
Nice one- I just discovered it about two weeks ago- impressed by huge ramp in sales- and I really think the co-combustion is going to be big.
Am trying to set up meeting with management for Q&A since I live nearby.
$MNGA: MagneGas Corporation (MNGA): Strong Sales Growth + Pending Co-Combustion Technology Launch = Strong Buy
Article @ http://microcapresearch.com/magnegas/
Looks like BV has increased to $3+
$46.7m in shareholder equity on 15.4m shares = ~ $3.03
There is no preferred equity to deduct.
I wish ARCW had stuck with their business focus (as I understood it anyway) from two years ago of growing 3DMT/3D printing in part by using their existing MIM operations/contacts.
3DMT is by far the fastest growing part of the business (135% in last Q) and I believe they could have had similar growth at 3DMT without all the dilution and CAPEX that really gave EPS a hit. This is the same issue with DDD and SSYS of course, and it's not something they're going to turn around in the next Q either based on their dim outlook for fy Q1.
They still need to file the 10-K
So I'm not sure what the actual BV is now- but I suspect it's about the same (maybe higher after the financing earlier this year) despite hit to bottom line.
I'm holding here- but not adding either.
3DP stocks in general seem to have been forming a bottom the last few weeks- hopefully it's not just another temporary bottom- like they've done for the last 18 months now.
HEAVY insider and institutional buying in $VGGL
see article
http://microcapresearch.com/viggle-record/
$ARCW now trading at book value.
Wow
Book value is $2/share- so would be surprised to see it go much lower than it is right now at $2.30
Well, since I've been so wrong on ARCW for the last 6 months or so- I'm probably not the person you want to ask.
But I will say that I listened to the conference call- and it, along with the what's in the press release on Q1 outlook...was pretty grim.
The 3D printing service part of the business is the lone bright spot.
So- not sure if market has overreacted- the company has not met analyst estimates for the last 4 quarters now. ARCW was one heck of a high growth, EPS-ramping stock... until they went too aggressive (in my opinion) with acquisitions that they're still trying to absorb over a year later.
Back in their fiscal Q2 and Q3, they sounded somewhat optimistic that they had turned the corner- so I thought Q4 would be the breakout for them with a return to bottom line growth. Now...it looks like a positive turn won't come until their fiscal Q2 according to the press release and conference call. So I don't think shares will bounce back strongly very fast.
Anyway- I've been so wrong about ARCW lately that shares could be over $4 next week for all I know-
yep- and while it may not be all that positive for those who bought at higher prices, GGG has still outperformed all other 3D printing stocks since day of trading - present.
The "quick" money was made in the first few months of trading- when stock went from .70 to $2.50...but I completely believe there will be another BIG leg up- and more sustained this time- based on fundamentals/strong revenue growth.
Once they report revenues (over $1M), the stock will start getting more traction.
I suspect there are several large investors in rights offering- which was the case earlier this year at $2/share - and price action today suggests things look good.
So yes, I am exercising my rights (again) because this stock will fly (again) when offering is completed and acquisition is made.
Stock traded right around/above $2 when that rights offering was being worked thru- and there were a lot of naysayers- but it all worked out with stock doubling in about 2 months.
$SITO Recent Highs Just the Beginning for Disruptive Mobile Advertising Company
http://microcapresearch.com/sito-mobile-2/
3D Printed Circuit Boards using GGG.V / GPHBF Graphene Filaments
https://3dprintingstocks.com/3d-printed/
$ARCW - Well...
lost .04/share vs. estimate of + .02/share and Q1 outlook pretty weak...
http://finance.yahoo.com/news/arc-group-worldwide-inc-reports-203000772.html
$LL 50 dma is $16.50
http://stockcharts.com/c-sc/sc?s=LL&p=D&b=5&g=0&i=0&r=1442416201061 …
With 1/3 of float short it could get interesting if it closes above $16.50 today
$DDD insider buying
Last 3 months
56,000 shares bought vs .8,000 shares sold http://www.nasdaq.com/symbol/ddd/insider-trades/buys …
yes- ugly day with no bounce.
I sold/small gain.
$TTPH- I took starter here also. Agree 80% plunge looks overdone given cash position and fact company has other drugs in late stage trials.
The rebate rate (interest rate) charged to short HOTR just went from 7% to 20% this week.
That makes shares an expensive short. Expect some covering.
$VGGL - Nice news in premarket
With 2.4M shares short, this could get interesting.
I guess it depends on how "commercial development" is defined.
If they consider the feasibility study with Sysmex part of commercial development, then absolutely- they've already disclosed that. To me though, "commercial development" means more.
I did get an update today...but they're still very cautious in discussing the work with Sysmex and did not give any real details. This is the same as it's been since the beginning of the year- very conservative in what they will say at this point.
I did get a feeling that things are continuing down the road with Sysmex and that it (most likely) is just a matter of time before something substantive in terms of a production & sales contract is finalized.
Nice. For those who remember the big run back in March...
It began with shares trading just around the rights offering was priced at ($2/share). There were a LOT of naysayers who said management wouldn't get the rights offering completed...they'd fail, etc.
Well management got the offering done and stock doubled over the next 6-8 weeks.
I fully expect the same thing to happen now. Keep in mind it will only take a handful of large investors to complete the offering- these are investors that know the coming acquisition buzz following the rights offering will be good for a big move in the stock. That's how it played out in March and how it will play out now in my opinion.
I'll be updating my subscribers at MicrocapResearch.com with 2 updated articles on HOTR in the next week. Share price has never been better and fundamentals, particularly + EBITDA has never been better.
COAG "Currently in Commercial Development"
Web site page for COAG reads
"Patented technology currently in commercial development with a global hematology partner"
Link: http://www.bioamd.com/technology/blood-coagulation-monitor
This was sent to me by a subscriber of mine who has been watching the site. He says language this is new/updated- and I believe he's right.
I think I would have remembered if I read the words "currently in commercial development" at the very top of the page- because it's my understanding that Sysmex and BIAD were in discussions that BIAD hoped/expected would lead to commercial development.
Does anyone remember this language being used on the site earlier? "currently in commercial development"
I emailed the company last week asking for clarification but haven't heard back yet.
Agree
I've added a few last two days in $1.30-$1.32s and plan to participate in subscription.
I'm in no rush- will slowly buy just like I did when subscription in beginning of year was underway. Once that's concluded and acquisition complete, the stock will be a flyer again. Until then- patience will be the key.
Congrats XXII shareholders.
Much more to come as FDA submission for modified risk ciggs. gets underway-
Read more of our thoughts on XXII, our latest pick, (up 25% in a bear market since our recommendation), here:
http://microcapresearch.com/upcoming-fda-submission-xxii/
I'm buying back now, yes.
I bought the first rights offering early in year and that set the bottom for the stock.
This will be a repeat of that, with $1.35 rights offering (priced today) setting the bottom. Expect news soon that will get it going again.
Obviously a very weak market right now- but low gas prices = good news for fast casual restaurant growth.
Also have spoken with the CEO on several occasions and like his style, brains, and ability to execute.